Letter from the Editor EditorProf. Gert Ossenkoppele, Amsterdam UMC, the Netherlands ConferenceEHA 2024 12 August 2024 14:12
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials ExpertProf. C. Ola Landgren, University of Miami, FL, USA ConferenceEHA 2024 10 July 2024 16:53
EHA 2024 Highlights Podcast Presented ByRobert van den Heuvel, Medicom ConferenceEHA 2024 2 July 2024 21:58
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial Presented ByProf. Thierry Facon, University of Lille, France TrialPhase 3, IMROZ ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:19
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM Presented ByProf. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands TrialPhase 3, PERSEUS ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:17
Post-intensification data confirm superiority of quadruple therapy in MM Presented ByProf. Marc Raab, University Hospital Heidelberg, Germany TrialPhase 3, GMMG-HD7 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:17
Promising phase 1 results for novel CAR T-cell therapy in MM Presented ByDr Binod Dhakal, Medical College of Wisconsin, WI, USA TrialPhase 1 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:17
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM Presented ByProf. Meletious Dimopoulos, University of Athens, Greece TrialPhase 3, DREAMM 8 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:16
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL Presented ByProf. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain TrialPhase 3, PhALLCON ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:25
APOLLO: ATRA plus ATO meets expectations in high-risk APL Presented ByProf. Uwe Platzbecker, Leipzig University Hospital, Germany TrialPhase 3, TUD-APOLLO-064 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:25
Excellent phase 3 results for asciminib in chronic myeloid leukaemia Presented ByProf. Andreas Hochhaus, Jena University Hospital, Germany TrialPhase 3, ASC4FIRST ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:25
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy Presented ByDr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA TrialPhase 2, AUGMENT-101 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:24
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML Presented ByDr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA TrialPhase 2 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:20
CD40/CD47 inhibitor shows promise in high-risk MDS and AML Presented ByProf. Amer Zeidan, Yale University, CT, USA ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:19
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS Presented ByDr David Sallman, Moffitt Cancer Center, FL, USA TrialPhase 3, ENHANCE ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:19
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS? Presented ByDr Anne Sophie Kubasch, University of Leipzig, Germany TrialPhase 2, RELAZA2 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:19
Can WGTS replace standard-of-care diagnostics in AML? Presented ByDr Anna Staffas, University of Gothenburg, Sweden ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:19
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia Presented ByProf. Ali Taher, American University of Beirut, Lebanon TrialPhase 3, ENERGIZE ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:26
Sovleplenib delivers durable responses and QoL improvements in primary ITP Presented ByProf. Renchi Yang, Chinese Academy of Medical Sciences, China TrialPhase 3, ESLIM-01 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:26
Avatrombopag successful in children with chronic ITP Presented ByDr Rachael Grace, Harvard Medical School, MA, USA TrialPhase 3, AVA-PED-301 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:26
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease Presented ByDr Rabi Hanna, Cleveland Clinic, OH, USA TrialPhase 1/2, RUBY ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:25
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis Presented ByDr Abhishek Maiti, MD Anderson Cancer Center, TX, USA TrialPhase 1 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:25
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis Presented ByProf. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA TrialPhase 3, TRANSFORM-1 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:28
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis? Presented ByDr Raajit Rampal, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, MANIFEST-2 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:28
The landscape of TP53 mutations and their prognostic impact in CLL Presented ByDr Consuelo Bertossi, University Hospital Ulm, Germany ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 15:11
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL? Presented ByDr Marc Hoffman, The University of Kansas Cancer Center, KS, USA TrialPhase 1, CC-220-DLBCL-001 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:27
High survival rates following atezolizumab consolidation in DLBCL Presented ByDr Marcel Nijland, University Medical Center Groningen, the Netherlands TrialPhase 2, HOVON 151 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:27
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL Presented ByProf. Paolo Ghia, University Vita-Salute San Raffaele, Italy TrialPhase 3, SEQUOIA ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:27
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation Presented ByProf. Arnon Kater, University of Amsterdam, the Netherlands TrialPhase 1/2, EPCORE CLL-1 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:27
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes Presented ByDr Evgenii Shumilov, University of Münster, Germany ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:27
ECHO: Can we expect a novel standard of care in newly diagnosed MCL? Presented ByProf. Michael Wang, University of Texas, TX, USA TrialPhase 3, ECHO ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:26
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups Presented ByDr Sarit Assouline, Jewish General Hospital, Canada TrialPhase 1/2 ConferenceEHA 2024 TypePeer-reviewed article 12 August 2024 14:26